Canaccord lowers Boston Scientific stock price target on Watchman slowdown By Investing.com

Canaccord cut Boston Scientific’s price target to $70 from $71 while reiterating a Buy rating, citing slower U.S. Watchman growth in 2026-2027, higher interest expense, and accelerated buybacks in its revised model. The stock was quoted at $48.31, near its 52-week low of $48.12, as other analysts also adjusted outlooks around Watchman and broader growth expectations. The news is modestly negative for sentiment but mainly reflects analyst re-rating rather than a fundamental surprise.

Analysis

The setup is less about one product line and more about a credibility reset: when multiple sell-side firms converge on slower medium-term growth, the stock can remain cheap longer than valuation models imply because the market starts discounting management’s next few guideposts rather than the current year. That creates a classic “value trap vs. rerating” battleground where buybacks cushion downside, but they do not fix the core issue if organic growth in a key franchise decelerates for several quarters.

Second-order winners are likely to be names with cleaner growth narratives in adjacent structural niches: if this category’s growth is questioned, capital rotates toward peers with stronger procedural visibility and less product-concentration risk. Within medtech, suppliers and competitors tied to alternative solutions may see a marginal benefit as investors seek exposure to the same end-market without the same single-product overhang.

The key catalyst window is the next 2-3 earnings prints, not the next 2-3 weeks. If management can show that the slowing segment is a timing issue rather than an inflection in demand, the stock can re-rate quickly off depressed expectations; if not, consensus will likely keep drifting lower, and the current multiple will compress further despite the buyback support. The biggest tail risk is that accelerated repurchases are interpreted as a confidence signal when they may simply be a capital-allocation response to a stalled growth profile.

The contrarian read is that the selloff may be somewhat overdone versus the broader franchise quality: the market is pricing a permanent growth impairment before the evidence base is complete. That said, in a market rewarding visible top-line acceleration, a “cheap BSX” argument is usually insufficient unless there is a clear catalyst for upside revision. I would treat this as a stock-specific execution story, not a sector-wide bearish call.

Key Decisions for Investors

• Fade the rebound: short BSX into strength over the next 1-4 weeks, using prior support as a risk line; thesis is multiple compression persists until the market sees proof that Watchman deceleration is transitory.
• For a cleaner expression, pair long a higher-visibility medtech grower vs. short BSX for 3-6 months; goal is to isolate growth-quality dispersion rather than taking broad healthcare beta.
• If already long BSX, monetize downside protection via 3-6 month put spreads rather than outright liquidation; the stock can grind lower even if fundamentals stay intact, but buybacks limit a crash scenario.
• Watch the next 1-2 quarterly updates closely: if organic growth guidance is reiterated and sell-side revisions stabilize, cover shorts quickly because the first inflection in estimates can trigger a sharp short squeeze off a low base.